It is certainly no understatement to say that 2020 has been a very tough year in many ways, but it has not stopped scientific progress and the great strides and studies that have been reported over the course of the year.

Should all breast cancer patients have germline genetic testing? That is a topic getting a lot of attention and was the question tackled by a pair of expert clinician-scientists during a special SABCS 20 debate.

The I-SPY trials have become models to accelerate the development of personalized treatment for breast cancer patients. In this year’s Brinker Clinical Research Award Lecture, I-SPY Principal Investigator Laura Esserman, MD, MBA, discussed the vision and goals for I-SPY 2 and beyond.

As one of the world’s leading experts in the science of estrogen receptor signaling and a pioneer in the development of SERMs and SERDs, Donald McDonnell, PhD, says one of the questions he is asked most frequently is which of these is most suitable and most likely to work best in metastatic breast cancer.

Early circulating tumor cell dynamics were associated with overall survival in patients with metastatic breast cancer, according to a meta-analysis presented during General Session 4 at SABCS 20 on Friday, Dec. 11.

In the same way the pandemic couldn’t stop the 43rd annual San Antonio Breast Cancer Symposium, the founders of GRASP are determined to continue the program they launched at SABCS 19.

The Joe R. and Teresa Lozano Long San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The Long School of Medicine designates this live activity up to a maximum of 46.75 AMA PRA Category 1 Credits™.